SVB Leerink Initiates Coverage On Tango Therapeutics with Outperform Rating, Announces Price Target of $25
SVB Leerink analyst Andrew Berens initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Outperform rating and announces Price Target of $25.
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera’s COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 16)
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 9)
The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 7)
72 Biggest Movers From Yesterday
Gainers
Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.
Three Analysts Initiate Coverage On This Newly Listed Precision Oncology Firm
Wedbush initiated coverage of Tango Therapeutics Inc (NASDAQ:TNGX) with an Outperform rating and a $12 price target. Analyst Robert Driscoll believes Tango’s…
